FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311586518> ?p ?o ?g. }

• W4311586518 endingPage "1038" @default.
• W4311586518 startingPage "1026" @default.
• W4311586518 abstract "Acute graft-versus-host disease (aGvHD) is a life-threatening complication typically occurring within 100 days after allogeneic hematopoietic cell transplantation (allo-HCT). This hypothesis-generating, phase II, prospective, open-label, randomized study (clinicaltrials gov. Identifier: NCT03339297) compared defibrotide added to standard-of-care (SOC) GvHD prophylaxis (defibrotide prophylaxis arm) versus SOC alone (SOC arm) to prevent aGvHD post-transplant. This study estimated incidences of aGvHD and was not statistically powered to assess differences among treatment arms. Patients were randomized 1:1 to defibrotide prophylaxis arm (n=79; median age 57 years; range, 2-69 years) or SOC arm (n=73; median age 56 years; range, 2-72 years). Patient demographics in the two arms were similar except for conditioning regimen type (myeloablative: defibrotide, 76% vs. SOC, 61%) and stem cell source for allo-HCT (bone marrow: defibrotide, 34% vs. SOC, 26%). In the intent-to-treat primary endpoint analysis, the cumulative incidence of grade B-D aGvHD at day 100 post-transplant was 38.4% in the defibrotide prophylaxis arm versus 47.1% in the SOC arm (difference: -8.8%, 90% confidence interval [CI]: -22.5 to 4.9). The difference noted at day 100 became more pronounced in a subgroup analysis of patients who received antithymocyte globulin (defibrotide: 30.4%, SOC: 47.6%; difference: -17.2%; 90% CI: -41.8 to 7.5). Overall survival rates at day 180 post-transplant were similar between arms, as were the rates of serious treatment-emergent adverse events (defibrotide: 42%, SOC: 44%). While the observed differences in endpoints between the two arms were not substantial, these results suggest defibrotide prophylaxis may add a benefit to currently available SOC to prevent aGvHD following allo-HCT without adding significant toxicities." @default.
• W4311586518 created "2022-12-27" @default.
• W4311586518 creator A5007524891 @default.
• W4311586518 creator A5008162182 @default.
• W4311586518 creator A5038572126 @default.
• W4311586518 creator A5040919350 @default.
• W4311586518 creator A5047829491 @default.
• W4311586518 creator A5050987906 @default.
• W4311586518 creator A5058209680 @default.
• W4311586518 creator A5089245881 @default.
• W4311586518 creator A5089418637 @default.
• W4311586518 creator A5090179241 @default.
• W4311586518 date "2022-12-15" @default.
• W4311586518 modified "2023-09-30" @default.
• W4311586518 title "A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation" @default.
• W4311586518 cites W1596160021 @default.
• W4311586518 cites W1964045655 @default.
• W4311586518 cites W1973519172 @default.
• W4311586518 cites W2002093270 @default.
• W4311586518 cites W2004055810 @default.
• W4311586518 cites W2013819874 @default.
• W4311586518 cites W2015629236 @default.
• W4311586518 cites W2022991931 @default.
• W4311586518 cites W2027216818 @default.
• W4311586518 cites W2038815061 @default.
• W4311586518 cites W2039808932 @default.
• W4311586518 cites W2045254759 @default.
• W4311586518 cites W2050750274 @default.
• W4311586518 cites W2052605694 @default.
• W4311586518 cites W2066216766 @default.
• W4311586518 cites W2107611068 @default.
• W4311586518 cites W2116483603 @default.
• W4311586518 cites W2126021331 @default.
• W4311586518 cites W2145708130 @default.
• W4311586518 cites W2147068163 @default.
• W4311586518 cites W2148164607 @default.
• W4311586518 cites W2155722011 @default.
• W4311586518 cites W2164885965 @default.
• W4311586518 cites W2233256572 @default.
• W4311586518 cites W2290703194 @default.
• W4311586518 cites W2328513032 @default.
• W4311586518 cites W2330300975 @default.
• W4311586518 cites W2342148351 @default.
• W4311586518 cites W2597974085 @default.
• W4311586518 cites W2603665507 @default.
• W4311586518 cites W2604688936 @default.
• W4311586518 cites W2612498493 @default.
• W4311586518 cites W2687087437 @default.
• W4311586518 cites W2769990542 @default.
• W4311586518 cites W2917040403 @default.
• W4311586518 cites W2979912543 @default.
• W4311586518 cites W3001557001 @default.
• W4311586518 cites W3014544491 @default.
• W4311586518 cites W3017245290 @default.
• W4311586518 cites W3033273678 @default.
• W4311586518 cites W3038797253 @default.
• W4311586518 cites W3042288668 @default.
• W4311586518 cites W3094154390 @default.
• W4311586518 cites W3116635973 @default.
• W4311586518 cites W3145694737 @default.
• W4311586518 cites W3180036174 @default.
• W4311586518 cites W3193510987 @default.
• W4311586518 cites W3203113184 @default.
• W4311586518 cites W3204376130 @default.
• W4311586518 cites W4205710683 @default.
• W4311586518 cites W4207003022 @default.
• W4311586518 cites W4239968098 @default.
• W4311586518 doi "https://doi.org/10.3324/haematol.2022.281471" @default.
• W4311586518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36519326" @default.
• W4311586518 hasPublicationYear "2022" @default.
• W4311586518 type Work @default.
• W4311586518 citedByCount "1" @default.
• W4311586518 countsByYear W43115865182023 @default.
• W4311586518 crossrefType "journal-article" @default.
• W4311586518 hasAuthorship W4311586518A5007524891 @default.
• W4311586518 hasAuthorship W4311586518A5008162182 @default.
• W4311586518 hasAuthorship W4311586518A5038572126 @default.
• W4311586518 hasAuthorship W4311586518A5040919350 @default.
• W4311586518 hasAuthorship W4311586518A5047829491 @default.
• W4311586518 hasAuthorship W4311586518A5050987906 @default.
• W4311586518 hasAuthorship W4311586518A5058209680 @default.
• W4311586518 hasAuthorship W4311586518A5089245881 @default.
• W4311586518 hasAuthorship W4311586518A5089418637 @default.
• W4311586518 hasAuthorship W4311586518A5090179241 @default.
• W4311586518 hasBestOaLocation W43115865181 @default.
• W4311586518 hasConcept C126322002 @default.
• W4311586518 hasConcept C141071460 @default.
• W4311586518 hasConcept C168563851 @default.
• W4311586518 hasConcept C197934379 @default.
• W4311586518 hasConcept C203092338 @default.
• W4311586518 hasConcept C2777408962 @default.
• W4311586518 hasConcept C2777712501 @default.
• W4311586518 hasConcept C2779972918 @default.
• W4311586518 hasConcept C2781413609 @default.
• W4311586518 hasConcept C2911091166 @default.
• W4311586518 hasConcept C71924100 @default.
• W4311586518 hasConcept C88879693 @default.
• W4311586518 hasConceptScore W4311586518C126322002 @default.

• next